HOW GOOD ARE OUR MEDICINES?
An operational agenda for EU & national policy-makers
At the European Health Forum Gastein
Organised by Open Society Foundations (OSF) in cooperation with the European Alliance for Responsible R&D and Affordable Medicines (European Alliance),
and the European Public Health Alliance (EPHA)
Evidentiary requirements and the medicines regulatory framework in Europe are integral parts of the access to medicines debate and deserve much more attention. Our session builds on last year’s agenda-setting session and will outline actionable recommendations for medicines regulatory reform in order to achieve meaningful public health needs-driven innovation for the benefit of all patients.
Furthermore, the conference comes at a critical juncture when Europe is debating the role of Health Technology Assessment (HTA), and how to ensure that public investment in medical R&D translates to the medicines we need being developed and made available at prices that patients and governments can afford. The session will draw the link between HTA and the regulatory environment and provide answers to the conundrum of weak evidence-high prices faced by policy-makers across Europe.
The session will be highly interactive and no presentations will be allowed in order to guarantee a lively and comprehensive conversation amongst panelists and with the audience.
Programme
Welcome
Introductory remarks
Kiti Kajana Phillips, Open Society Foundations
PANEL 1
Assessing the Quality of Innovation
– Wolf-Dieter Ludwig, Chairman, Drug Commission, German Medical Association and EMA Management Board member
– Ameet Sarpatwari, PhD.J.D, Instructor in Medicine, Harvard Medical School, Associate Epidemiologist at Brigham and Women’s Hospital, Assistant Director of the Program On Regulation, Therapeutics And Law (PORTAL), Harvard University
– Natasha Azzopardi-Muscat, President, European Public Health Association (EUPHA)
– Bart Vermeulen, Deputy Director Healthcare, Office of the Minister of Social Affairs and Public Health, Belgium
Moderated by Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines, EPHA, Board Member, EHFG
PANEL 2
Case Studies & Tools for Change
– Caroline Izambert, Citizen advocacy and campaigns coordinator, AIDES, France
– Representative of Altroconsumo
– Adrian van den Hoven, Director General, Medicines for Europe
– Vanessa Lopez, Executive Director of Salud por Derecho (Spain)
Moderated by Daniel Wolfe, Open Society Foundations
Re-live the event
Event Gallery
Courtesy of EHFG 2018: Health and Sustainable Development – bold political choices for Agenda 2030
Event Webcast
Courtesy of EHFG 2018: Health and Sustainable Development – bold political choices for Agenda 2030
Re-live the online discussion
#goodmedicines
Public good perspective is missing from the holy trinity of the European Medicines Agency's regulatory approval process of quality, safety, efficacy. #EHFG2018 @EMA_News #goodmedicines
— GHA EU (@GHABrussels) October 3, 2018
“Shortages of medicines can become a choice between life&death for people. Competition authorities must bear that in mind and act asap.” @lcrisigiovanni at #EHFG2018 #goodmedicines
— Catta (@CattaFra) October 3, 2018
#GoodMedicines #EHFG2018 Wolf-siete Ludwig from the German Medicines Agency states that prices of #OrphanDrugs, tested on very few patients, demonstrates that we are not paying #medicines based on R&D expenses.
— Charlotte Roffiaen (@EU4Ublog) October 3, 2018
More than 800.000.000 € is the cost of the SPC in Truvada for the French health system. @assoAIDES & other organisations in Europe ask for the review of the SPC regulation. Isn't it time to prioritize patients, public heath and protect national budgets? #EHFG2018 #GoodMedicines
— Viviana Galli (@Vivivovi) October 3, 2018